key: cord-0912499-f24yuckj
authors: Sekine, Leo; Arns, Beatriz; Fabro, Bruna R.; Cipolatt, Murillo M.; Machado, Rafael R. G.; Durigon, Edison L.; Parolo, Edino; Pellegrini, José Augusto S.; Viana, Marina V.; Schwarz, Patrícia; Lisboa, Thiago C.; Dora, José Miguel S.; Balsan, Almeri M.; Schirmer, Felipe da-Silva; Franz, Juliana P. M.; da-Silveira, Luciana M.; Breunig, Raquel C.; Petersen, Viviana; Sosnoski, Monalisa; Mesquita, Nanci F.; Volpato, Fabiana Caroline Z.; Sganzerla, Daniel; Falavigna, Maicon; Rosa, Regis G.; Zavascki, Alexandre P.
title: Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
date: 2021-07-08
journal: Eur Respir J
DOI: 10.1183/13993003.01471-2021
sha: d88b657dd9d2f42d4012fd80bf0562b6554d396f
doc_id: 912499
cord_uid: f24yuckj

BACKGROUND: The effects of convalescent plasma (CP) therapy hospitalised patients with coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect CP on clinical improvement in these patients. METHODS: This is an investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial. Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or SOC alone. The primary outcome was the proportion of patients with clinical improvement 28 days after enrolment. RESULTS: A total of 160 (80 in each arm) patients (66.3% were critically ill and 33.7%, severe) completed the trial. The median age was 60.5 years (interquartile range [IQR], 48–68), 58.1% were men and the median time from symptom onset to randomisation was 10 days (IQR, 8–12). Neutralising antibodies titres >1:80 were present in 133 (83.1%) patients at baseline. The proportion of patients with clinical improvement on day 28 was 61.3% in the CP+SOC and 65.0% in the SOC group (difference, −3.7%; 95% Confidence Interval [CI], −18.8%-11.3%). The results were similar in the subgroups of severe and critically ill. There was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes, including 28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support. Inflammatory and other laboratorial markers values on days 3, 7 and 14 were similar between groups. CONCLUSIONS: CP+SOC did not result in a higher proportion of clinical improvement on at day 28 in hospitalised patients with COVID-19 compared to SOC alone.

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can cause severe illness in a considerable proportion of infected patients leading to severe progressive pneumonia, multiple organ dysfunction and death [1, 2] .

Passive immunotherapy using convalescent plasma (CP) collected from COVID-19 recovered patients has been advocated for the treatment of severe cases of this disease [3] . The US Food and Drug Administration issued an emergency use authorization for CP for the treatment of hospitalized patients with COVID-19 based on results of observational studies showing that CP was safe and could be associated with better clinical outcomes [4, 5] . Nevertheless, the two existing randomised clinical trials at the time of authorization [6, 7] and further multicentre randomised clinical trials [8, 9] have failed to demonstrate significant clinical benefit of CP in patients with severe COVID- 19 . The long duration of disease when intervention occurred and low neutralizing antibody titres in administered plasma may, at least partially, explain the absence of significant improvement in clinical outcomes in intervention groups in two of these trials [6, 7] . Other two larger clinical trials also did not find any benefit of CP on clinical outcomes. However, these studies used anti-SARS-CoV-2 spike IgG as a surrogate for neutralizing antibodies titres, impairing inferences that could be done on the baseline patient status regarding these antibodies and the investigated intervention [8, 9] .

Given the heterogeneity regarding CP characteristics, including volume, number of doses and neutralizing antibody titres, as well as distinct levels of pre-existing antibody titres at baseline in both intervention and control groups, further clinical trials with different administration strategies and distinct populations are necessary to better define the role of this therapy in hospitalized patients with severe COVID-19. In the present randomised clinical trial, we assessed the effect of two doses of 300 mL of CP therapy administered in the first 14 days of symptoms onset on clinical improvement in severe and critically ill COVID-19 patients. 

Patients admitted to the hospital were assessed for eligibility if they were 18 or older, had a positive reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 (Supplementary Material 2), had less than 15 days of initial symptoms onset, and had severe respiratory disease, as defined by the presence of at least one of the following: respiratory rate >30 breaths per minute in room air; oxygen saturation (O2) ≤93% in room air; arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤ 300; need for supplemental O2 to maintain O2 saturation >95%; need for supplemental O2 by high flow nasal cannula, non-invasive ventilation, or invasive mechanical ventilation. Exclusion criteria were impossibility for any reason to perform the first plasma infusion within 14 days of the onset of symptoms; use of immunosuppressive drugs for other non-COVID-19 underlying diseases in the last 30 days before enrolment; pregnancy; history of serious adverse reactions such as transfusion anaphylaxis; disagreement of attending physician; and participation in other interventional randomised clinical trials.

A full description of plasma donation selection and procedures is shown in Supplementary Material 2.

Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 hours apart of 300ml of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer-generated randomization with random block sizes of 2 or 4 and stratified according to the unit of hospitalization on enrolment (medical ward or intensive care unit [ICU] ; unit of hospitalization on enrolment was used as a proxy for disease severity). Patients and investigators were unmasked, except interviewers performing follow-up telephone calls, who was unaware of the assigned trial group.

The SOC for COVID-19 was at the discretion of the treating physicians. The use of glucocorticoids, other immunomodulators, antibiotic agents, and antiviral agents was allowed. Remdesivir was not available in Brazil during the trial period.

Definitions of baseline variables assessed in the baseline are presented in the Supplementary Methods. Neutralizing antibodies were determined in all donor plasma units and on patient serum collected on days 0 and 3 (after the second plasma infusion) after enrolment, following previously described protocol [10] . Nasal and oropharyngeal swabs were collected at day 7 after enrolment or at hospital discharge. Blood samples were collected on days 0 (pre-infusion), 3 (post second infusion), 7 and 14 after enrolment in hospitalized patients.

The primary outcome was the proportion of patients with clinical improvement 28 days after enrolment. Clinical improvement was defined as hospital discharge or reduction of 2 points in a 6-level ordinal scale. Levels on the scale were defined as follows: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation or extracorporeal membrane oxygenation; and 6, death. Prespecified secondary outcomes included RT-PCR for SARS-CoV-2 from nasal and oropharyngeal swab at day 7 from enrolment or hospital discharge (if earlier than 7 days); clinical status assessed using the 6-level ordinal scale and all-cause mortality at days 14 and 28 after enrolment; time to hospital discharge and days alive and free of supplemental oxygen support (non-survivors and patients requiring oxygen support at day 28 were assigned as 0 supplemental oxygen support free-days) within 28 days from enrolment; Sequential Organ Failure Assessment (SOFA) score and National Early Warning Score 2 (NEWS) 2 on day 7 after enrolment; and length of invasive ventilatory support (for those who received mechanical ventilation). Adverse events were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 adverse up to day 28 after enrolment or hospital discharge. Other prespecified exploratory outcomes were levels of serum inflammatory markers and cytokines, measured on days 3, 7 and 14 after enrolment (Supplementary Material 2).

Patients were followed daily up to day 28 after enrolment or hospital discharge by researchers who were aware of the trial-group assignments. For patients who were transferred to another hospital before day 28, a structured telephone call to the patient or the patient's family was conducted by an interviewer to assess the level on the ordinal scale at day 28.

We had originally planned for the trial to include 160 patients considering all-cause mortality within 28 days as the primary outcome and an absolute difference between arms of 20% to achieve a power of 80%, using the formula for two binomial proportions and two-sided tests, as described by Rosner [11] . However, due to the evolving knowledge on COVID-19, the steering committee assumed that a reduction of 20% in mortality would be very unlikely to occur and that estimated proportions for survival and death within 28 days were better suited for clinical response. Therefore, it was decided to submit a protocol amendment on July 27, 2020 (when eight patients had been included in the trial) modifying the primary outcome to clinical improvement on day 28 after enrolment.

In the revised sample size calculation, assuming a proportion of clinical improvement of 60% in the SOC group (Supplementary Material 2), a sample of 160 patients (80 in each arm) was estimated to achieve a power of 80% to detect an absolute difference of 20% or greater in the proportion of patients with clinical improvement at day 28 with a 2sided α level of .05. Other modifications are detailed in the study protocol in Supplementary Material 1.

Data were primarily analysed according to the intention to treat principle. The proportion of patients with clinical improvement on day 28 and relative risk were assessed using robust Poisson regression. Prespecified subgroups were defined according to the unit of hospitalization (medical ward [considered severe patients] or ICU [considered critically ill patients]) and mechanical ventilation needed on enrolment. Consistency of intervention effects on the primary outcome across these subgroups was assessed by means of interaction tests.

A post-hoc sensitivity analysis was performed for the primary outcome considering a per-protocol population. Secondary outcomes were compared Generalized Linear Models, according to the probability distribution of the outcome, or with the Wilcoxon-Mann Whitney test as appropriate. The potential effect of variables with a P value ≤0.20 at the baseline on the primary outcome was addressed in Poisson regressions models.

Also as an exploratory analysis considering the clinical improvement outcome as a reduction of 1 point in the ordinal scale.

One pre-planned interim analysis for efficacy and safety evaluation after 80 patients with complete follow-up was conducted (Supplementary Material 2). The stopping rule for efficacy and safety was a P value<.05. There was no adjustment in the final threshold for statistical significance for sequential analysis.

All analyses were performed using the R software version 4.0.2 (R Core Team). No adjustments for multiplicity were performed. Thus, the results of secondary outcomes and subgroup analyses should be interpreted as exploratory. A 2-sided P value of less than 0.05 was considered statistically significant.

From July 15 to December 10, 2020, 496 patients were assessed for eligibility. Of these, 160 were eventually enrolled: 80 in the CP+SOC group, and 80 in the SOC alone group ( Figure 1 ). The follow-up was completed on January 7, 2021. A total of 106 (66.3%) patients were located at the ICU and 54 (33.7%) at the medical ward at randomization.

Baseline characteristics are shown in Table 1 . The median age was 60.5 years (interquartile range [IQR], 48.0-68.0), 93 (58.1%) were men, and the median time from symptom onset to randomization was 10 days (IQR, [8] [9] [10] [11] [12] . A total of 133 (83.1%) patients presented neutralizing antibody titres above 1:80 at randomization (median, 1:1280; IQR, 1:320-1:2560). All but 2 (1.2%) patients were receiving glucocorticoids at the time of entry into the trial. The baseline characteristics of the participants enrolled in CP+SOC group and of those enrolled in SOC alone group were similar, except for median neutralizing antibody titres, which were significantly higher in control than in intervention group, and interleukin-6 levels, which significantly higher in intervention thank in control group (Table 1 and Supplementary Material 2) .

Sixty-two (77.5%) patients received the CP from the same donor, while 15 (18.8%) received the second infusion from a distinct donor. The median neutralizing antibody titres from donors' plasma administered to patients from the intervention group was 1:320 (IQR, 1:160-1:960), which was significantly lower than baseline neutralizing antibody titres of patients previously to the infusion (P <0.001). Only five donors' plasma had neutralizing antibody titres lower than 1:80 (four 1:40 and one 1:20) . Other characteristics of CP donors are shown in Supplementary Material 2.

Two patients allocated to CP (1.3%) did not receive any intervention (1 due to the lack of compatible plasma units and 1 patient that died before receiving transfusion) and other two patients (1.3%) did not receive the second plasma infusion. One patient allocated to CP received four additional plasma infusions pending on discretion of the attending physician. One patient allocated to the control group received one unit of CP, also on discretion of the ICU team.

On day 3, there was a significantly higher increase in neutralizing antibody titres in the intervention than in control group (P =0.001) in relation to titres at randomization (day 0) (Figure 2 

The safety population included 79 patients who received at least one infusion of CP and 81 patients who received only SOC. A total of 52 (65.8%) and 48 

There was no significant difference in no prespecified subgroup analysis by age and neutralizing antibody titres at baseline (Supplementary Material 2). There was no significantly difference between intervention and SOC groups in Poisson regression models including variables with a P value ≤0.20 at the baseline (Table 3 ). There was also no significantly difference in clinical improvement on day 28, considering this outcomes as an one point reduction in the ordinal scale (61.3% vs. 68.8% in intervention and control groups, respectively; RR, 0.89 [95%CI, 0.71-1.12]; P =0.33).

In this randomised clinical trial with severe and critically ill COVID-19 patients, CP therapy administered in the first 14 days of the onset of symptoms plus SOC did not significantly increase the proportion of clinical improvement on day 28 compared with SOC alone. Similar results were found in both critically ill and patients hospitalized at medical ward subgroups. These findings are consistent with previous randomised clinical trials that could not find significant benefit of CP in hospitalized patients with COVID-19 [6] [7] [8] [9] .

There were also no significant differences in clinical and laboratorial outcomes between intervention and control groups, including 14-and 28-day mortality, clinical status on days 14 and 28 assessed by an ordinal scale, days free of ventilation, days of hospitalizations and SOFA and NEWS2 scores. No difference was observed considering one point reduction in the ordinal scale as clinical improvement.

One strength of our study is that virtually all patients were treated with corticosteroids, mostly dexamethasone, as SOC and other drugs were not used. Additionally, this study was the first to evaluate some laboratory exams in patients' follow-up. The demonstration of absence of difference in these markers are consistent with clinical findings and help to reduce the level of uncertainty on the potential benefit of CP in severe COVID-19. Notably, in contrast to Li et al. [6] we could not find any difference in SARS-CoV-2 RT-PCR positivity rate between groups.

As found in a previous trial [7] , most of the patients included in the study have already presented high levels (above 1:80) of neutralizing antibody titres at randomization. These titres were even higher in the SOC group (more than 75% of patients with titres equal or greater than 1:640). Two infusions of 300 ml of CP increased the levels of these antibodies on day 3 in the intervention group. The increase in neutralizing antibody titres from randomisation to day 3 was significantly higher in intervention group, and although the levels were higher in intervention than in control on day 3, this difference was not statistically significant probably because baseline levels in the former group was lower than the later. Nonetheless, this increase seemed to have no impact on both clinical and laboratorial outcomes, as indicated by the absence of any significant difference of inflammatory markers between groups in any point of collection from day 0 to 14. It must be acknowledged that the presence of high levels of neutralizing antibodies titres at randomization favours the null hypothesis, even though the effect on primary outcome was not affected when adjusted for this variable in the Poisson regression model. Furthermore, it is highly relevant from a pragmatic perspective, i.e., increment in antibody response in patients through passive administrations does not seem to be worthy in patients with severe COVID-19.

Notably, patients in the intervention group presented significantly higher levels of interleukine-6 at randomisation. Although interleukin-6 levels, as other variables analysed in Poisson regression models, did not significantly modify the effect of convalescent plasma on the outcome, and we at first attributed is as a casual difference that may be observed even with the randomisation process, we can not fully rule out that patients in intervention arm might be more severely ill. However, as shown in sensitivity analysis, if present, this would not be a disbalance able to affect the main results of the study.

A recently published meta-analysis evaluated the effect of CP on mortality and other clinical outcomes, including preprint publications and a press release of one randomised trial, could not find any significant difference of this strategy from SOC or placebo [12] .

Given the heterogeneity of doses, neutralizing antibody titres and time of CP administration, along with the fact that most randomised trials have been prematurely interrupted, as pointed out by the authors, the certainty of the evidence was low to moderate for all-cause mortality and low for other clinical outcomes. We updated that meta-analysis using the same methodology, including data from a preprint publication [9] previously available only as a press release, and PLACOVID trial for mortality. The This study has some limitations First, it is an open-label study and data collectors were not blinded to the patients' group assignment. Despite not finding a positive effect of intervention, potential biases associated with this design cannot be completely ruled out.

Second, our clinical trial is a single-centre study in a COVID-19 reference tertiary-care university-affiliated hospital, which may impair the generalizability of the findings; however, the overall findings point towards the same direction of previous multicentre studies. Third, this study is composed mostly by critically ill patients, a group of patients whose potential benefit could be less expected. Nonetheless, similar results were found in both critically ill and patients hospitalized at medical ward. Finally, we were underpowered to evaluate the efficacy in patients with low neutralizing antibody titres. Despite the low number of patients, the exploratory analysis of patients with titre Along with previous studies suggesting a potential benefit with CP [13] or monoclonal antibodies in early periods of mild to moderate COVID-19 [14, 15] patients with severe COVID-19 and low levels of neutralizing antibodies might still be a group of interest for future studies with passive immunotherapy.

In conclusion, in severe or critically ill COVID-19 patients, almost all receiving corticosteroids as SOC, CP+SOC did not result in a higher proportion of clinical improvement on day 28 compared to SOC alone. Data are n (%), median (Interquartile Range) or mean ± standard deviation. Abbreviations: PaO2/FiO2, arterial oxygen partial pressure /fractional inspired oxygen; NEWS, National Early Warning Score; SOFA, Sepsis-Related Organ Failure Assessment. # P = 0.15. This variable was selected for post hoc analysis by a Poisson regression model to adjust the effect of intervention. ¶ P = 0.11. This variable was selected for post hoc analysis by a Poisson regression model to adjust the effect of intervention. + Ten control (12.5%) and 10 convalescent plasma (12.5%) had PaO2/FiO2 estimated from peripheral oxygen saturation /FiO2 ratio adjusted to the positive endexpiratory pressure. One patient (1.3%) in the intervention group and one (1.3%) in the control group did not collect blood samples for neutralizing antibody titre measurement. One (1.3%) patient in the intervention group did not collect D-dimer; one (1.3%) patient in the control group did not collect interleukin-6 and tumor necrosis factor-alpha at randomization. § P = 0.002 for median neutralizing antibody titres and P = 0.041 for neutralizing antibody titre ≤1:80. Median neutralizing antibody titres was selected for post hoc analysis by a Poisson regression model to adjust the effect of intervention. ǂ Leukocyte counts and inflammatory markers: P = 0.14 for median white blood cell count; P = 0.17 for median neutrophil count; P = 0.16 for C Reactive Protein; P = 0.11 for D-dimer; P = 0.046 for Interleukine-6; and P = 0.20 for Tumor Necrosis Factor-alpha. These variables were selected for post hoc analysis by a Poisson regression model to adjust the effect of intervention. ǁ Among patients who were treated with corticosteroids, 78 (99.7%) and 77 (97.5%) received dexamethasone in plasma convalescent and control groups, respectively. Other corticosteroid drugs were used in 10 (12.7%) and 16 (20.1%) patients from intervention and control groups, respectively. 

Passive antibody therapy involves administering antibodies against a specific agent to prevent or treat infectious disease caused by that agent. Conversely, active vaccination requires an immune response to occur, which requires time and varies by recipient. Thus, the administration of passive antibodies is a way of providing immediate immunity to susceptible/infected people. These antibodies can be obtained through convalescent serum from the plasma of recovered patients.

The use of this therapeutic modality to treat infectious diseases began around 1890 1 and continued until 1940, when antimicrobials became the first line of treatment for bacterial diseases.

Nevertheless, the use of antibody-based therapy has been expanded to include pathologies caused by poisons, toxins and some viral infections (rabies, hepatitis A and B, chickenpox and pneumonia caused by the respiratory syncytial virus) 2 .

Antibody-based therapy has evolved since 1975, when a method of producing monoclonal antibodies by immortalized B cells was discovered 3 . It thus became possible for the first time to produce large quantities of immunoglobulins of a predefined specificity and isotope in vitro. This technique culminated in the development of several monoclonal antibodies, which are mainly used to treat neoplasms, rheumatological diseases and prevent rejection after transplants. However, the monoclonal antibody palivizumab has been approved for the prophylaxis of respiratory syncytial virus 4 .

Passive antibodies have been used to treat a range of infectious diseases ( which has been proven to suppress viral load and alter the cytokine profile (IL-6 induces the release of IL-10, which can be important in neutralizing the effects of inflammatory cytokines), as well as mechanisms such as viral inactivation, in addition to dispensing with ABO compatibility. The greatest disadvantage of this type of therapy is the preparation time: convalescent plasma requires approximately 2-6 weeks, while H-IVIG requires approximately 6 months to produce 5-8 .

In the 20th century, convalescent serum was used to treat outbreaks of viral diseases such as polio 9 , measles 10 , rubella 11 and influenza 12 . A retrospective meta-analysis of 8 studies that used convalescent serum to treat 1703 patients during the H1N1 (Spanish flu) epidemic in 1918 suggested that treated patients had lower mortality 13 . It is important to note that, historically, convalescent serum has been used when there was no means of measuring antibody titers, as well as in clinical studies that did not meet current criteria for randomization or blinding 14 .

In addition, convalescent serum was used during the 2009-2010 H1N1 influenza virus pandemic in intensive care patients. Obtained through apheresis, it reduced inflammatory response and mortality 15 . During the 2013 Ebola epidemic, treating patients with convalescent whole blood led to increased survival rates 14 . Similar reports have also been published regarding H5N1 16,17 and H7N9 18 .

One of the main advantages of antibodies is their high specificity; they do not alter host flora or select resistant microorganisms. Another advantage is their different biological effects, since they are natural products of the immune system and can interact with similar components. In addition to neutralizing toxins and viruses, they can activate the complement system and cause a direct antimicrobial effect, all of which are host independent. They can also stimulate cell cytotoxicity and opsonization. Antibodies also function as immunomodulators, being effective against microorganisms for which they do not mediate a direct biological effect 2 .

Antibodies can function in their intact form or through fragments. In the intact molecule, the variable region binds to the antigen, while the constant region determines the biological properties of the immunoglobulin molecule, interacts with cellular receptors, and activates the complement. When working against a toxin or virus, only one fragment is necessary to mediate the binding effect of the variable region to the antigen. Intact molecules are required when efficacy depends on interaction with effector cells to mediate phagocytosis or to direct cell cytotoxicity 2 . The effect of mimicking and actively participating in the immune response against the pathogen is an important advantage of this type of therapy.

Its high specificity means that more than one antibody preparation may be required to target microorganisms with antigenic variation 2 . There is also a temporal issue, ie, the therapy is more effective when provided at the beginning of the infection. This makes rapid diagnosis essential. In infectious diseases, the effectiveness of this therapy is known to be reduced after symptom onset [19] [20] [21] .

The use of convalescent serum also entails risks related to blood transfusions, such as infections due to the transmission of other pathogens, as well as reactions to serum constituents, which can lead to serum sickness. However, the rigorous modern techniques used in hemotherapy centers are designed to reduce these risks.

Administering plasma to individuals with lung disease (such as individuals with severe forms of COVID-19) can lead to complications, such as transfusion-related acute lung injury 22 Antibody-dependent enhancement is a theoretical risk related to the use of convalescent serum. This phenomenon has mainly been described in in vitro studies of viral diseases; certain mechanisms have been described in relation to coronaviruses and there is concern that antibodies against one type of coronavirus could enhance another viral chain 23 . However, since convalescent serum against SARS-CoV-2 would be composed of high antibody titers, there is less risk of antibody-dependent enhancement.

Another theoretical risk would be that the administration of passive antibodies could attenuate the body's natural immune response. A study that administered passive antibodies against respiratory syncytial virus prior to vaccination found that humoral immunity was attenuated, although cellular immunity was not altered 24 . This area should also be investigated for SARS-CoV-2 and, if the risk is real, individuals who have received passive antibodies should be vaccinated as soon as possible.

Since its inception in Wuhan, China in late 2019, COVID-19 has globally affected more than 1,900,000 people, causing more than 120,000 deaths. It was declared a pandemic by the World Health 

Passive antibody-based therapy has already been used in other coronavirus outbreaks, such as SARS-CoV-1 40 . In the case of SARS-CoV-2, the anticipated mechanism of action would be viral neutralization. However, other mechanisms may be possible, such as direct antibody-mediated cell toxicity and phagocytosis 14 .

Possible sources of antibodies against SARS-CoV-2 include convalescent serum from patients who have recovered from COVID-19, monoclonal antibodies, or preparations from animal hosts.

Although the latter two are under development, convalescent serum is the only currently available option. Furthermore, as more infected individuals recover, the potential number of donors increases.

The therapy is based on assessing antibody levels against SARS-CoV-2 in patients who have recovered from COVID-19. If these patients have reasonable levels of antibodies, plasma is collected for infusion for severe cases or even as prophylaxis ( Figure 1 ).

In the 21st century, there have been two coronavirus epidemics associated with high mortality: The largest study to have used convalescent serum in these epidemics included 80 patients with SARS-CoV-1 in Hong Kong 41 . Patients treated before D14 had a better prognosis, which was defined as hospital discharge before D22. In addition, patients with positive SARS-1 C-reactive protein and negative antibody titers had a better response to this therapy. Convalescent serum was also used in critically ill patients; 3 SARS patients in Taiwan were treated with 500 mL of convalescent serum 42 and survived, in addition to 3 Middle East respiratory syndrome patients in South Korea 43 .

An analysis of 99 convalescent serum samples from recovered SARS patients found that 87 had antibodies, with a geometric mean titer of 1:61 44 , which suggests that production decreases over time; thus, collection must be carried out promptly.

Chinese studies have reported using this therapy to treat critically ill patients with COVID-19 45 . Despite small samples, their results suggest that convalescent serum can reduce viral load and improve risk scores, such as the Sequential Organ Failure Assessment (SOFA) score. 

The SARS-CoV-2 pandemic and its global implications for health systems and human behavior require emergency measures. Thus, if Brazil and the state of Rio Grande do Sul undergo the aggressive infection scenarios estimated by mathematical models, the health system will be overcrowded with seriously ill patients. The Hospital de Clínicas de Porto Alegre (HCPA), a reference center for humanized, quality health care in many sectors, is part of a network specifically developed to combat SARS-CoV-2. In line with its institutional mission to provide the best available care to patients, during the current crisis we propose using convalescent plasma to treat severe COVID-19 patients.

Historically, in adverse situations, health services must prioritize effective and speedy use of the best available evidence. At various times in history, convalescent plasma has been shown to be effective in combating viral diseases, including coronavirus infections, and it is currently being investigated in several world centers. In this context, randomized clinical trials are needed to define the role, if any, of convalescent plasma in the treatment of patients with severe covid-19.

The administration of convalescent plasma in patients with severe covid-19 has no effect of clinical improvement within 28 days compared to standard of care.

The administration of convalescent plasma in patients with severe covid-19 increases the proportion of patients with clinical improvement within 28 days compared to standard of care.

To evaluate the impact of convalescent plasma therapy on the frequency of clinical improvement within 28 days.

This investigator-initiated, unicentric, randomized, parallel arm, open-label, superiority clinical trial will evaluate patients severely affected by COVID-19 who receive convalescent plasma as an adjunct therapy during standard of care, as compared to a control group who receive standard of care alone.

The convenience sample will include patients aged18 years or older admitted to HCPA with a COVID-19 diagnosis who meet the study eligibility criteria.

The primary outcome was the proportion of patients with clinical improvement 28 days after enrollment. Clinical improvement was defined as hospital discharged or reduction of 2 points in a 6level ordinal scale. Levels on the scale were defined as follows: a score of 1 indicated not hospitalized;

2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation or extracorporeal membrane oxygenation; and 6, death.

The clinical response criteria for convalescent plasma infusion include mortality from any cause by D14 and D28, length of ICU stay, duration of mechanical ventilation and impact on ventilatory 

The donor search will be conducted by telephone contact with patients and collaborators (hospital employees) who underwent RT-PCR assays at HCPA and who meet the study inclusion criteria. There will also be a media campaign to recruit donors using current HCPA Hemotherapy Service recruitment tools. 

Convalescent plasma will be collected by apheresis. This procedure is performed when collecting only one component of whole blood, resulting in higher yield than the conventional donation process. In this case, the component of interest is the plasma, which contains antibodies against SARS-CoV-2. The collection will be carried out at the HCPA Hemotherapy Service using peripheral access venipuncture, through which the donor's blood will be drawn and subsequently reinfused. Processing is performed with disposable kits in a closed system, which allows the blood components to be separated by centrifugation. Plasmapheresis will be performed with a Spectra Optia leukapheresis system (Terumo BCT, Lakewood, CO, USA) and the respective intermediate density lipoprotein kit (or equivalent). The collected plasma volume will depend on certain donor factors: sex, weight, clinical condition on the day of collection, tolerance to the procedure, and blood count parameters on the day of collection. Maximum of 8 and 9 mL/kg of plasma are intended for women and men, respectively. The collected samples will be stored in appropriate bags in 300 ml aliquots at -20 to -30˚C.

A first 300 mL fresh-frozen plasma will be defrosted according to institutional routine and will be administered on the day of the patient's enrollment in the study (D0) and a second administration of 300 mL of fresh-frozen plasma on D2.The infusion will be performed according to institutional routines. The transfusion will be suspended if there are any adverse reactions and a transfusion reaction investigation will be opened.

In addition to the mandatory blood donation tests required (serology for hepatitis B, hepatitis C, Chagas disease, human T-cell lymphotropic virus type I/II, syphilis and nucleic acid amplification testing for hepatitis B, hepatitis C and HIV), additional blood samples will be collected from convalescent patients for subsequent measurement of SARS-CoV-2 specific IgG and IgM antibodies.

The ethical aspects of clinical trials are of crucial importance, since they are interventional studies, and patient safety is always a priority. However, it is important to point out the unique situation of proposing a therapy during a pandemic. When the lives of thousands of people are threatened and no specific therapy exists, it may be ethically acceptable to accept greater risks and offer patients interventions whose effectiveness has not been conclusively proven 46 . Similar discussions about experimental therapies occurred during the Ebola epidemic [47] [48] [49] . In general, in extreme situations and after discussion with the local community, novel therapies have been approved since no other effective alternatives existed.

To assess the ethical validity of clinical trials in unique situations, the Doctors Without Borders Ethics Council proposed an evaluation structure, which is attached to the project as Questionnaire 2 49 .

It is important to point out that both donors and recipients (or their family/guardians) must provide written informed consent prior to the procedure. Donor risks: exposure to a blood bank environment during the COVID-19 pandemic; peripheral venous access (venous puncture), including local hematoma, pain, and leakage; possible adverse effects during donation, including plasmapheresis, although there is usually has a low incidence of serious complications. The rate of adverse events of any type during the procedure ranges from 4 to 5%. Complications are described in Table 2 50 .

An interim analysis will be performed when 50% of the patients have been randomized (80 patients, 40 in each group) and complete the 28-day follow-up. The interim analysis will be conducted confidentially by an independent consultant who is blinded to patient allocation. The results of the interim analysis will be reported to the Independent Data and Safety Monitoring Committee (IDSMC).

The criteria for interrupting the experimental treatment (which consists of an infusion of fresh frozen plasma on one or two occasions, depending on the attending physician's judgment) include serious adverse reactions attributed to the transfusion, such as: a) allergic reactions that worsen ventilatory or hemodynamic patterns; b) transfusion-related acute lung injury; c) febrile non-hemolytic reactions that impair proper sepsis management; c) any other serious adverse events as determined by the health care team.

The criteria defined for interrupting the study at the interim analysis are: a statistically significant difference in primary outcome (clinical response) and overall 28-day mortality between the intervention groups, or the occurrence of serious adverse events, whether predicted or not, in the intervention group, as assessed by the IDSMC. Equivalence between the groups for the previouslymentioned outcomes at the interim analysis will not be considered a reason for interrupting the study.

The IDSMC will consist of 5 members who are completely independent (directly or indirectly) of the study, and who may or may not be affiliated with the HCPA, including at least 1 hematologist, 1 intensive care physician, and 1 statistician. The other members will include other health professionals and researchers with recognized experience in clinical studies.

All adverse events observed in enrolled patients of either group will be immediately reported to the IDSMC. Any serious complications, even if not primarily associated with the intervention, will be regularly reported to the IDSMC. The IDSMC's evaluation will occur on a weekly basis (or when treatment interruption for an enrolled patient is required) and will be transmitted to the lead researcher, who will be responsible for implementing its decisions in the research group.

The activities of the IDSMC will include the assessment of adverse effects reported in enrolled patients and determining whether treatment should be interrupted when any relevant criteria are observed. Likewise, the IDSMC will be responsible for determining any adverse events not previously anticipated in the study design, as well as for their clinical investigation and final attribution to the intervention. The IDSMC will also be responsible for the interim analysis, as well as the decision to interrupt the study.

The monitoring and analysis of adverse events will be carried out by the Research Subcommittee on Safety and Quality, which is also responsible for other interventional studies on COVID-19 at HCPA (statement attached as a supplement). Table 3 shows the main immediate transfusion reactions, which are of great concern for the present project 50 . 

With a power of 80% and a 95% confidence interval, to find an increase from 60% to 80% in the rate of clinical improvement within 28 days between the control and intervention groups, 160 equally distributed patients (80 per group) will be required.

Depending on the normality analysis, the data will be presented as mean ± SD or as median and percentiles. Comparisons between groups will be made with Student's t-test, the Wilcoxon-Mann-Whitney test, ANOVA, or Pearson's chi-square test, as appropriate. Pearson's or Spearman's test will be used to determine correlations between the variables. The primary outcome will be assessed between the groups with the chi-square test. Survival analysis will be performed using the Kaplan Meyer curve. P <0.05 will be considered statistically significant. All statistical analyses will be performed in SPSS, version 21.0 (SPSS Inc., Chicago, IL, USA). The primary endpoint and the main secondary endpoints will be assessed in a priori-defined subgroups, namely: patients admitted to the ward vs. ICU at randomization, patients on vs. not on mechanical ventilation at randomization. A summary of the statistical analysis plan for the primary and secondary endpoints is summarized in the Table 4 (below). Difference between the control and intervention groups in the frequency of clinically improved patients by D28.

Time until clinical improvement in both groups. Deaths or hospitalizations on D28 will not be considered.

Deaths at D14 and D28

Difference between the control and intervention groups in the frequency of deaths by D14 and D28.

Time until death in the control and intervention groups by D28. Living patients on D28 will not be considered.

Clinical condition at D14 and D28

Difference in frequency (proportion) between groups for patients at each clinical stage according to the 6-point assessment scale

Chi-square NEWS 2 score in relation to baseline on D7 and D14

(1) Comparison of median group scores on D7 and D14 and (2) Change in NEWS 2 score between groups in relation to baseline.

(1) Wilcoxon-Mann-Whitney test (2) Simple linear regression.

Ventilator-free days until D28 Difference in the mean or median (according to the variable's distribution) of the time that participants are alive and ventilator-free until D28. The death rate will be zero.

Length of hospital stay Difference in length of hospital stay between groups. (1) Mean and median among the survivors and (2) time until the outcome between the groups (the entire population) excluding deaths and patients still hospitalized on D28.

(1) Student's t-test or the Wilcoxon-Mann-Whitney test (2) Logrank Mechanical ventilation time Difference in the mean or median (according to the variable's distribution) of the time that patients on ventilation at the time of enrollment remained ventilated. Only survivors will be considered. Patients on mechanical ventilation on D28 will not be considered.

Quantitative laboratory tests (1) Comparison of mean or median scores between groups on D3 and D7 and (2) Change in relation to the baseline between the groups.

(1) Student's t-test or the Wilcoxon-Mann-Whitney test (2) Simple linear regression.

Difference in frequency of positive tests on D7 (or earlier if discharged) between the intervention and control groups Chi-square

Difference in the frequency of adverse effects between the intervention and control groups.

Chi-square or Fischer's exact test

The expected result is to achieve the primary outcome: a higher rate of clinical improvement within 28 days in severe COVID-19 patients who receive convalescent plasma. Additionally, the expected improvement of other analysis parameters, especially length of ICU stay, duration of mechanical ventilation and the length of hospital stay, may provide benefits at both an individual and a community level. How this pathology will evolve in the local community is still uncertain, and there is a risk that the existing health resources may be insufficient for the demand. Thus, it is of great interest to develop therapies that can reduce the use of specialized services, such as those offered by HCPA.

The study's development and execution schedule is shown in Table 5 .

• Patients with confirmed SARS-CoV-2 infection will be invited to participate in the study through telephone contact if they fulfill the above-mentioned clinical criteria for donors;

• Patients arrive at the HCPA for blood-donor screening; if the screening criteria are met, the above-mentioned specimen collection procedures are performed and plasmapheresis is scheduled;

• The donor returns to the blood bank for plasmapheresis, and a volume to be determined by individual characteristics will be collected;

• The plasma is processed in aliquots and frozen;

• The potential recipient is evaluated according to the above-described inclusion criteria;

• The recipient receives the plasma sample according to the institution's infusion routine;

• The recipient is monitored daily by the research team until hospital discharge;

• Telephone contact is made with the donor 30 days after the donation to check for any delayed signs/symptoms related to the donation. 

The convalescent plasma collection and infusion risks have been described above. The study has some viability issues: the 160 total patients (80 in the intervention group) required to find the estimated outcome is a considerable number and it is not known how long it will take to achieve it. It is possible that both the number of cases and a lack of consent will be barriers.

Another possible difficulty concerns finding available donors. The donation process is completely voluntary, which means that some convalescent patients will not be available. The

Hemotherapy Service team is working daily on fundraising strategies to overcome this barrier. These strategies will also be applied to the overall project, and it is hoped that during the pandemic community involvement will be widespread. 4) The first inclusion criteria referred to no more than 3 days of hospitalization as an eligibility criterion.

This had been shown problematic for two reasons: i) the research team was not prepared to recruit all patients within this short timeframe and many potential candidates with early symptoms would be lost;

and ii) Since our hospital is a reference covid-19 hospital in the state of Rio Grande do Sul, many patients had been transferred from another hospital and, although they were within the first days in our hospital, we would have to account for this period of hospitalization in other hospitals and it would undesired workload. Finally, it seemed more plausible that time from onset of symptoms would better define those who would most likely benefit from convalescent plasma. comparability with other studies. Some procedures were also depending on an additional budget that has been approved and released as the study was ongoing, as detailed above.

In the registration on clinicaltrials.gov we also included an additional secondary endpoint:

days alive and free of respiratory support. This endpoint was judged to be relevant in the assessment of therapeutic interventions for severe covid-19 patients and had not been considered previously.

These modifications as registered in clinicaltrials.gov were communicated to the Brazilian National Commission for Research Ethics on January/05/2021. We also included the evaluation of neutralizing antibodies titers, since the budget for dosing neutralizing antibodies had been approved in the last two weeks of patients enrollment. The risks of administering convalescent plasma have been described in detail in the research project.

What is the possible social damage? The research team will dedicate part of its time to research rather than direct assistance.

c. What is the process for monitoring unknown harm? A team member will be assigned to assess possible harm during the event.

(2.2) What are the plans for obtaining consent?

Donor consent will be obtained after a clear explanation of the risks and benefits of donation. Recipient consent will be obtained through family members/guardians, since, in their clinical situation, the patients cannot provide it.

a. What information will be provided? The reasons for conducting the research, information from the researchers, and details about the risks and benefits of the intervention.

b.

Will the information be provided in written and oral form? Yes, by the research team.

(2.3) What is the plan to maintain confidentiality?

Patient data is already subject to the hospital's confidentiality policy. Thus, only active researchers will be able to participate in the data collection and updating process.

(2.4) What is the plan for accessing, storing and distributing the collected biological material?

The HCPA blood bank already has specific policies for plasma collection and storage. These rules will be applied to the present research project.

An Open-Label, Randomised Clinical Trial

Potential plasma donors were procured both among healthcare workers from the institution and candidates from the community. Eligible donors were required to be male or nulliparous females, between 18 and 60 years of age, asymptomatic from COVID-19 for at least 14 days

and have a negative oropharyngeal/nasal swab RT-PCR for SARS-CoV-2 on the day of plasma donation, as well as fulfil all regulatory requirements for blood donation. During the donor qualification process, complete blood count, ABO and RhD typing, and serological tests were performed both for bloodborne diseases (conventional blood donation tests) and

for SARS-CoV-2 IgG. Only candidates with a positive results (according to chemiluminescent assay criteria) for SARS-CoV-2 IgG were qualified for donation.

Selected convalescent plasma (CP) were collected from male or nulliparous females, aged between 18 and 60 years old, with previous COVID-19 confirmed either by RT-PCR or positive IgG serological test. Donors were required to be asymptomatic for at least 14 days before plasma donation and comply with all regional conventional regulatory requisites for blood donation. An additional IgG anti-SARS-CoV-2 nucleocapsid test (Abbott Laboratories) was performed in all candidates to confirm serological status at the moment of donation. All donors were required to sign an informed consent acknowledging the research nature of their participation.

Convalescent plasma was collected from previously qualified donors through apheresis procedure on a Fenwal Amicus Separator (Fenwal, Lake Zurich, IL) with a modified singleneedle plateletpheresis protocol. Standard anticoagulant ACD-A solution was used during procedures. For each plasma donation, a target of 600-700 ml of convalescent plasma was set up. Individual donors were allowed to donate additional units with a minimum interval of 14 days between procedures.

The presence of diabetes, cardiovascular disease (coronary heart disease, cerebrovascular disease, and peripheral vascular disease), and chronic pulmonary disease (chronic obstructive pulmonary disease and asthma) were accounted as registered in medical records. Obesity was defined as a body mass index equal to or higher than 30.

PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fraction of inspired oxygen. Arterial blood gases were ordered at the discretion of patients' medical teams and were not performed in all patients. When PaO2 was not available, this ratio was substituted by the peripheral oxygen saturation (SaO2)/FiO2 ratio adjusted to the positive end-expiratory pressure (PEEP), as previously reported. [1] This later ratio was also imputed for the calculation of SOFA score when PaO2 was not available. Bilirubin was measured only if deemed medically necessary. When no bilirubin was available and there was no record of previous hepatic disease, we imputed zero points for the liver component of the score. [2] Vasoactive drugs at baseline were either noradrenaline or vasopressin.

Neutralizing antibodies (nAbs) were determined in all plasma bags and on serum collected on the day of enrolment (day 0) and 3 days after CCP transfusions. The titration of nAbs was performed using the cytopathic effect-based virus neutralization test (CPE-based VNT) with SARS-CoV-2/human/BRA/SP02cc/2020 strain virus (GenBank access number: MT350282.1)

[3], following a previously described protocol. [4] Briefly, 5×10 Vero cells/mL (ATCC CCL-81) were seeded 24 hours before the infection in a 96-well plate. Serum samples were, initially, inactivated for 30 min at 56°C. We used 11 dilutions (two-fold) of each serum (1:20 to 1:20,480). Subsequently, serum was mixed vol/vol with 1000 TCID50/mL of the virus and preincubated at 37°C for 1 hour to allow virus neutralization. Then, the serum plus virus mixture was transferred onto the confluent cell monolayer and incubated for 3 days at 37°C, under 5%

CO2. After 72 hours, the plates were analysed directly under transmitted-light bright-field microscopy (Olympus Co., Tokyo, Japan). The virus neutralization titre referred to VNT100 is described as the highest dilution of serum that neutralized virus growth (absence of cytopathic effect). All the procedures related to CPE-VNT were performed in a biosafety level 3 laboratory, at the Institute of Biomedical Sciences -University of São Paulo, in accordance with WHO recommendations. [5] Blood samples were drawn on days 0 (day of randomization; before infusion in the intervention group), 3 (after infusion of the second plasma bag in the intervention group), 7, and 14. A total of 5 mL whole blood with K2 EDTA (dipotassium ethylenediaminetetraacetic acid -Vacuette®, Greiner Bio-One, Kremsmünster, Austria) was immediately centrifuged, separated, and plasma stored at −20ºC until analysis.

The following laboratory markers were evaluated on days 3, 7, and 14 after randomization:

lactate dehydrogenase, troponin I, C-reactive protein, D-dimers, fibrinogen, prothrombin

The estimated proportion of patients exhibiting clinical improvement on day 28 was based on the findings of Li et al., [7] in which this rate was 43.1 % in the control group. We expected a higher proportion of patients presenting 2 points of improvement on the ordinal scale, because the median time from the onset of symptoms to randomization in that trial was 30 days for the control group; thus, we presumed that patients would be more likely to exhibit a 2-point improvement on the scale if followed from an earlier moment after the onset of symptoms. For the same reason, we expected that earlier administration and the second plasma bag could potentially result in a higher effect on clinical improvement rate at day 28 than that of the 8.8% difference observed by Li et al. [7] Supplementary Results Data are median (Interquartile Range) or mean ± standard deviation.

# Two (2.5%) patients in the intervention group did not have lactate dehydrogenase collected at randomization. ¶ One (1.3%) patient in the intervention group did not have fibrinogen, prothrombin time, or activated partial thromboplastin time measured.

A total of 48 plasma donors have performed 91 apheresis donations. Characteristics from convalescent plasma donors and procedure parameters can be found in eTable1. Thirty (62.5%) of these donors performed two or more plasma donations during trial. The median neutralizing antibody titres from donors' plasma administered to patients from the intervention group was 1:320 (IQR, 160 to 1:960). Only five donors' plasma eventually had neutralizing antibody titres lower than 1:80 (four 1:40 and one 1:20). 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

The convalescent sera option for containing COVID-19

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Safety Update: COVID-19 Convalescent Plasma

Hospitalized Patients

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program

Boston : Brooks/Cole, Cengage Learning

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

To assess the impact of convalescent plasma on length of intensive care unit (ICU) stay

To assess the impact of convalescent plasma on the time of mechanical ventilation and ventilatory parameters

To assess the impact of convalescent plasma on SOFA score

To assess the impact of convalescent plasma on length of hospital stay

To evaluate the therapy's association with other clinical variables, including age, gender, time from symptom onset, symptoms presented

To assess the therapy's association with other complications, such as shock, acute cardiac injury and arrhythmia

To assess the therapy's safety with respect to transfusion complications

Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren

Passive antibody therapy for infectious diseases

Continuous cultures of fused cells secreting antibody of predefined specificity

Prevention of respiratory syncytial virus infection in infants

Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Therapeutic use of antipoliomyelitits serum in preparalytic cases of poliomyelitis

The prophylactic use of measles convalescent serum

Mumps: Use of Convalescent Serum in the Treatment and Prophylaxis of Orchitis

Hark back: passive immunotherapy for influenza and other serious infections

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

The convalescent sera option for containing COVID-19

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of

Successful treatment of avian influenza with convalescent plasma

Treatment with convalescent plasma for influenza A (H5N1) infection

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma

Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers

Antibody-mediated regulation of cellular immunity and the inflammatory response

Serum therapy revisited: animal models of infection and development of passive antibody therapy

Transfusion-related acute lung injury in the critically ill: prospective nested case-control study

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine 2020

Gilead Sciences Statement on the Company's Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

First Case of 2019 Novel Coronavirus in the United States

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

China approves use of Roche drug in battle against coronavirus complications

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

A serological survey on neutralizing antibody titer of SARS convalescent sera

Use of convalescent plasma therapy in SARS patients in

European journal of clinical microbiology & infectious diseases : official publication of the

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

A framework for risk-benefit evaluations in biomedical research

Research ethics and international epidemic response: the case of Ebola and Marburg hemorrhagic fevers

Ethics of conducting research in conflict settings

Research ethics review in humanitarian contexts: the experience of the independent ethics review board of Medecins Sans Frontieres

Guia para uso de hemocomponentes

D-dimers were analysed by optical reaction in a Siemens Sysmex CS2500 system

Coagulation parameters (prothrombin time, activated partial thromboplastin time and fibrinogen) were determined in a Stago STA R Max analyzer

) were used to measure IL-6 and TNF-alpha, respectively. The tests were performed as per the manufacturer's instructions. Provided standards (low and high control) were used to monitor the assay. In brief, 50 mL of plasma were added to each well with same volume of assay buffer (1x) for IL-6 and Sample Dilution solution for TNF-alpha

The RT-qPCR assay for SARS-CoV-2 was performed as previously described, based on CDC guidelines

of SuperScript™III RT/Platinum™ Taq Mix; 0.2 µL of ROX (1:10); 0.75 µL of combined primers/probes mix of nCOV1 (N1 primer) or nCOV2 (N2 primer) or RP (2019-nCoV RUO Kit

Three different results were considered: "negative" when neither N1 nor N2 targets amplified; "positive" when both N1 and N2 amplified; and "inconclusive

Derivation and validation of Spo2/Fio2 ratio to impute for Pao2/Fio2 ratio in the respiratory component of the Sequential Organ Failure Assessment score

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program

SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network

Pooling of samples to optimize SARS-CoV-2 diagnosis by RT-qPCR: comparative analysis of two protocols

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

We are grateful to Dr Patrícia Prolla and the "Grupo de Pesquisa e Pós-Graduação